Vaccine29 Jul 2020 08:29
The vaccine candidate - developed by Paris-based pharmaceutical company Sanofi in partnership with Brentford, England-based drugmaker GSK - is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's pandemic adjuvant technology.
Roger Connor, president of GSK Vaccines, said: "We believe that this adjuvanted vaccine candidate has the potential to play a significant role in overcoming the Covid-19 pandemic, both in the UK and around the world."
Sanofi said it is leading the clinical development and registration of the Covid-19 vaccine and expects a phase 1/2 study to start in September, followed by a phase 3 study by the end of 2020.
If the data are positive, regulatory approval could be achieved by the first half of 2021.